Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BookCitation
.... 14.5 BookPartCitation
.... 14.6 CertaintyOfEvidence
.... 14.7 Classification
.... 14.8 CohortDefinition
.... 14.9 Comment
.... 14.10 ComparativeBaselineMeasureEvidence
.... 14.11 ComparativeEvidence
.... 14.12 ComparativeEvidenceReport
.... 14.13 ComparativeEvidenceReportSubject
.... 14.14 ComparativeEvidenceSynthesisReport
.... 14.15 ComparativeParticipantFlowEvidence
.... 14.16 ComparatorDefinition
.... 14.17 ComparatorGroup
.... 14.18 ComparatorOnlyEvidence
.... 14.19 Comparison
.... 14.20 CompositeRating
.... 14.21 DatabaseCitation
.... 14.22 DatabaseEntryCitation
.... 14.23 DataDictionaryCodeSystem
.... 14.24 DatasetCitation
.... 14.25 DateAsRating
.... 14.26 DichotomousPatientImportantOutcome
.... 14.27 EndpointAnalysisPlan
.... 14.28 EvidenceList
.... 14.29 EvidenceMap
.... 14.30 EvidenceMeasureReportPackage
.... 14.31 EvidenceReport
.... 14.32 EvidenceReportPackage
.... 14.33 EvidenceReportSubject
.... 14.34 EvidenceSynthesisEvidence
.... 14.35 EvidenceTableReportPackage
.... 14.36 ExposureDefinition
.... 14.37 ExposureGroup
.... 14.38 GroupAssignment
.... 14.39 GroupR6
.... 14.40 Guideline
.... 14.41 InterventionOnlyEvidence
.... 14.42 JournalArticleCitation
.... 14.43 M11Report
.... 14.44 M11ResearchStudy
.... 14.45 MetaanalysisEligibilityCriteria
.... 14.46 MetaanalysisOutcomeDefinition
.... 14.47 MetaanalysisStudyGroup
.... 14.48 NetEffectContribution
.... 14.49 NetEffectContributionList
.... 14.50 NetEffectContributions
.... 14.51 NetEffectEstimate
.... 14.52 NonComparativeEvidence
.... 14.53 OutcomeDefinition
.... 14.54 OutcomeImportance
.... 14.55 OutcomeList
.... 14.56 OutcomeMeasureReport
.... 14.57 ParticipantFlowEvidence
.... 14.58 ParticipantFlowEvidenceVariable
.... 14.59 ParticipantFlowReport
.... 14.60 PreprintCitation
.... 14.61 Rating
.... 14.62 Recommendation
.... 14.63 RecommendationAction
.... 14.64 RecommendationEligibilityCriteria
.... 14.65 RecommendationJustification
.... 14.66 RecommendationPlan
.... 14.67 ResearchStudyDataDictionary
.... 14.68 RiskOfBias
.... 14.69 SearchResults
.... 14.70 SearchStrategy
.... 14.71 SingleStudyEvidence
.... 14.72 SoaPlanDefinition
.... 14.73 SoftwareCitation
.... 14.74 StatisticModel
.... 14.75 StudyEligibilityCriteria
.... 14.76 StudyGroup
.... 14.77 SummaryOfFindings
.... 14.78 SummaryOfNetEffect
.... 14.79 SystematicReview
.... 14.80 SystematicReviewEligibilityCriteria
.... 14.81 SystematicReviewExcludedStudies
.... 14.82 SystematicReviewIncludedStudies
.... 14.83 VariableDefinition
.... 14.84 WebPageCitation
.... 14.85 ArtifactApprovalDate
.... 14.86 ArtifactAssessmentCompared
.... 14.87 ArtifactAssessmentDateAsRating
.... 14.88 ArtifactEffectivePeriod
.... 14.89 ArtifactLastReviewDate
.... 14.90 CharacteristicTiming
.... 14.91 EvidenceVariableClassifier
.... 14.92 EvidenceVariableConditional
.... 14.93 EvidenceVariableConstraint
.... 14.94 EvidenceVariableDataCleaning
.... 14.95 EvidenceVariableDataStorage
.... 14.96 EvidenceVariableMissingData
.... 14.97 EvidenceVariablePeriod
.... 14.98 ResearchStudyEstimand
.... 14.99 ResearchStudyExcludedStudy
.... 14.100 ResearchStudyIncludedStudy
.... 14.101 ResearchStudyNumberOfStudiesIdentified
.... 14.102 ResearchStudyNumberOfStudiesIncluded
.... 14.103 ResearchStudyResultAsComposition
.... 14.104 ResearchStudySaeReportingMethod
.... 14.105 ResearchStudySearchStrategy
.... 14.106 ResearchStudySponsorConfidentialityStatement
.... 14.107 ResearchStudyStudyAmendment
.... 14.108 ResearchStudySystematicReviewEligibilityCriteria
.... 14.109 StatisticModelExpression
.... 14.110 StatisticModelIncludeIf
.... 14.111 Evidence Report Contributor Role Value Set
.... 14.112 Evidence Variable Role Subtype Value Set
.... 14.113 Recommendation Justification Classifier Codes Value Set
.... 14.114 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
.... 14.115 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.116 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.117 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus.
.... 14.118 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.
.... 14.119 179899
.... 14.120 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.121 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.122 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.123 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.124 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.125 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.126 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.127 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.128 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.129 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.
.... 14.130 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.131 236948
.... 14.132 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.133 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.134 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.135 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.136 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.137 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.138 264323
.... 14.139 264328
.... 14.140 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models.
.... 14.141 265092
.... 14.142 265093
.... 14.143 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study.
.... 14.144 267506
.... 14.145 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns.
.... 14.146 270503
.... 14.147 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.148 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.149 279340
.... 14.150 279346
.... 14.151 279347
.... 14.152 27979893 (6). Glycemic Targets.
.... 14.153 282882
.... 14.154 282891
.... 14.155 282899
.... 14.156 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.157 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.158 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.159 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.160 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.161 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.162 30467172 Finding my inner Wonder Woman.
.... 14.163 33395
.... 14.164 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.165 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.166 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.167 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
.... 14.168 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.169 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example
.... 14.170 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.171 Adults_with_type_2_diabetes
.... 14.172 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.173 Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16
.... 14.174 Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17
.... 14.175 Bariatric_Surgery_RYGB_VSG_LAGB_BPD
.... 14.176 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.177 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.178 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.179 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.180 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.181 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
.... 14.182 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.183 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.184 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.185 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.186 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.187 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.188 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.189 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.190 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.191 CohortDefinition_At_least_2_risk_factors_for_stroke
.... 14.192 CohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.193 CohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.194 CohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.195 CohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.196 CohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity
.... 14.197 CohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans
.... 14.198 CohortDefinition_BMI_criteria_for_ADA_surgery_recommendation
.... 14.199 CohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.200 CohortDefinition_Cardiovascular_event
.... 14.201 CohortDefinition_Heart_failure_based_on_Phenotypes
.... 14.202 CohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration
.... 14.203 CohortDefinition_Nonfatal_myocardial_infarction
.... 14.204 CohortDefinition_Nonfatal_stroke
.... 14.205 CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter
.... 14.206 CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges
.... 14.207 CohortDefinition_Proxy_criteria_for_surgical_candidates
.... 14.208 CohortDefinition_Severe_obesity
.... 14.209 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.210 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.211 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.212 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.213 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.214 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.215 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.216 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.217 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.218 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.219 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.220 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.221 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.222 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.223 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.224 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.225 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.226 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.227 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.228 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.229 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.230 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.231 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.232 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.233 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.234 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.235 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.236 ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort
.... 14.237 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.238 ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD
.... 14.239 ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis
.... 14.240 ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort
.... 14.241 ComparatorGroup_Obese_patients_18_years_old_without_bariatric_surgery
.... 14.242 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.243 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.244 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.245 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.246 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.247 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.248 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.249 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.250 Computable_Publishing_LLC
.... 14.251 COVID_19PneumoniaHospitalizedAdult
.... 14.252 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.253 DatabaseCitation: Citation for FEvIR Platform
.... 14.254 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.255 DataDictionary: Measuring the Rate of Scientific Knowledge Transfer
.... 14.256 DataDictionary: phs003190
.... 14.257 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.258 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.259 Delany-Moretlwe 2022 clinical trial
.... 14.260 EBMImplementationGuideProfile Value Set
.... 14.261 EGFR_45_59
.... 14.262 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.263 EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.264 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.265 EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.266 EvidenceReportSectionCode Value Set
.... 14.267 EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery
.... 14.268 EvidenceVariableRoleSubtype Value Set
.... 14.269 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.270 ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin
.... 14.271 ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort
.... 14.272 ExposureVariable: Age (as continuous variable)
.... 14.273 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.274 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.275 ExposureVariable: pht013093.v1.p1 RACE
.... 14.276 ExposureVariable: pht013093.v1.p1 SEX
.... 14.277 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.278 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.279 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.280 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.281 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.282 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.283 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.284 Glucagon_Like_Peptide_1_GLP_1_receptor_agonists85394_C_85798
.... 14.285 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.286 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.287 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort
.... 14.288 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.289 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.290 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.291 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.292 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
.... 14.293 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.294 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.295 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.296 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.297 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.298 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.299 Investigator
.... 14.300 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.301 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.302 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.303 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.304 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.305 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.306 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.307 M11 IGBJ Protocol Example for EBMonFHIR IG
.... 14.308 M11 Report Template Instructions
.... 14.309 MAGIC-derived Evidence: All-cause mortality Comparator Evidence
.... 14.310 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.311 MAGIC-derived Evidence: Body weight Comparator Evidence
.... 14.312 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.313 MAGIC-derived Evidence: Cardiovascular mortality Comparator Evidence
.... 14.314 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.315 MAGIC-derived Evidence: Diabetic ketoacidosis Comparator Evidence
.... 14.316 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.317 MAGIC-derived Evidence: End-stage kidney disease Comparator Evidence
.... 14.318 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.319 MAGIC-derived Evidence: Genital infection Comparator Evidence
.... 14.320 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.321 MAGIC-derived Evidence: Health-related quality of life Comparator Evidence
.... 14.322 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.323 MAGIC-derived Evidence: Heart failure Comparator Evidence
.... 14.324 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.325 MAGIC-derived Evidence: Nonfatal myocardial infarction Comparator Evidence
.... 14.326 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.327 MAGIC-derived Evidence: Nonfatal stroke Comparator Evidence
.... 14.328 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.329 MAGIC-derived Evidence: Serious hyperglycaemia Comparator Evidence
.... 14.330 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.331 MAGIC-derived Evidence: Severe gastrointestinal events Comparator Evidence
.... 14.332 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.333 MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis
.... 14.334 MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up
.... 14.335 MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs
.... 14.336 Mortality at 14 days
.... 14.337 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.338 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.339 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.340 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.341 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.342 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.343 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.344 NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022
.... 14.345 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.346 NHANES LBDGLUSI: Fasting Glucose (mmol/L)
.... 14.347 NHANES LBXGLU: Fasting Glucose (mg/dL)
.... 14.348 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary
.... 14.349 NHANES SEQN Respondent Sequence Number
.... 14.350 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight
.... 14.351 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.352 Organ support-free days
.... 14.353 Outcome Importance Rating 100 of All-cause mortality
.... 14.354 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.355 Outcome Importance Rating 5 of New onset depression
.... 14.356 Outcome Importance Rating 5 of Remission of diabetes
.... 14.357 Outcome Importance Rating 5 of Treatment with opioids
.... 14.358 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.359 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.360 OutcomeDefinition: All-cause mortality
.... 14.361 OutcomeDefinition: Body weight
.... 14.362 OutcomeDefinition: Cardiovascular mortality
.... 14.363 OutcomeDefinition: Diabetic ketoacidosis
.... 14.364 OutcomeDefinition: End-stage kidney disease
.... 14.365 OutcomeDefinition: Genital infection
.... 14.366 OutcomeDefinition: Health-related quality of life
.... 14.367 OutcomeDefinition: Heart failure
.... 14.368 OutcomeDefinition: Nonfatal myocardial infarction
.... 14.369 OutcomeDefinition: Nonfatal stroke
.... 14.370 OutcomeDefinition: Serious hyperglycaemia
.... 14.371 OutcomeDefinition: Severe gastrointestinal events
.... 14.372 OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control
.... 14.373 OutcomeDefinition_Diabetes_in_remission
.... 14.374 OutcomeDefinition_HbA1c_at_12_months
.... 14.375 OutcomeDefinition_HbA1c_at_24_months
.... 14.376 OutcomeDefinition_HbA1c_at_36_months
.... 14.377 OutcomeDefinition_HbA1c_at_60_months
.... 14.378 OutcomeDefinition_HbA1c_at_6_months
.... 14.379 OutcomeDefinition_New_onset_depression
.... 14.380 OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke
.... 14.381 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.382 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.383 OutcomeVariable: HbA1c at 12 months
.... 14.384 OutcomeVariable: HbA1c at 24 months
.... 14.385 OutcomeVariable: HbA1c at 36 months
.... 14.386 OutcomeVariable: HbA1c at 6 months
.... 14.387 OutcomeVariable: HbA1c at 60 months
.... 14.388 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.389 OutcomeVariable: New onset depression
.... 14.390 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.391 OutcomeVariable: Remission of diabetes
.... 14.392 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.393 OutcomeVariable_All_cause_mortality
.... 14.394 OutcomeVariable_Treatment_with_opioids
.... 14.395 Participant Flow Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.396 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.397 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.398 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.399 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis
.... 14.400 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.401 ParticipantFlowMeasure: Exclusion from analysis
.... 14.402 ParticipantFlowMeasure: Inclusion in analysis
.... 14.403 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.404 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.405 Placebo
.... 14.406 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.407 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.408 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.409 Recommendation Justification Code System
.... 14.410 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.411 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.412 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.413 Remdesivir
.... 14.414 Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days
.... 14.415 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.416 Risk Of Bias Type Value Set
.... 14.417 Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide
.... 14.418 SearchResults: PubMed search for Wonder Woman
.... 14.419 SearchStrategyCharacteristicCode Value Set
.... 14.420 SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review
.... 14.421 SearchStrategy_PubMed_search_for_Wonder_Woman
.... 14.422 Severely_Obese_Adults_2018_Norwegian_Cohort
.... 14.423 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.424 Sodium_Glucose_Transport_Protein_2_SGLT2_inhibitors85394_I_85798
.... 14.425 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.426 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.427 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.428 StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial
.... 14.429 StudyEligibilityCriteria_Obese_patients_18_years_old
.... 14.430 StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group
.... 14.431 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.432 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.433 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
.... 14.434 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.435 SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer
.... 14.436 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.437 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.438 Therapeutic-dose anticoagulation with heparin
.... 14.439 Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis
.... 14.440 WebPageCitation: A HEvKA Update Summary